GLP1R and type 2 diabetes mellitus: The so-called incretin effect is significantly diminished or nonexistent in patients with type 2 diabetes (T2DM) compared to healthy participants, which makes the GLP-1 receptor (GLP-1R) a desirable target for antidiabetic management with GLP-1RAs.